[go: up one dir, main page]

MY198553A - Pharmaceutical composition comprising metformin and lobeglitazone - Google Patents

Pharmaceutical composition comprising metformin and lobeglitazone

Info

Publication number
MY198553A
MY198553A MYPI2018700643A MYPI2018700643A MY198553A MY 198553 A MY198553 A MY 198553A MY PI2018700643 A MYPI2018700643 A MY PI2018700643A MY PI2018700643 A MYPI2018700643 A MY PI2018700643A MY 198553 A MY198553 A MY 198553A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical composition
lobeglitazone
metformin
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MYPI2018700643A
Inventor
Min Kwan Cho
Teak Hwan Shin
Shin Jung Park
Eun Ji Shin
Jong Lae Lim
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of MY198553A publication Critical patent/MY198553A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a pharmaceutical composition comprising metformin or a pharmaceutically acceptable salt thereof and lobeglitazone or a pharmaceutically acceptable salt thereof and a pharmaceutical formulation comprising the same. The pharmaceutical composition can exhibit a synergistic effect on glycemic control and can block the potential of side effects, and the pharmaceutical formulation can be provided in the form of a combination formulation that is able to be administered once a day to thus improve medication compliance.
MYPI2018700643A 2015-10-28 2016-08-24 Pharmaceutical composition comprising metformin and lobeglitazone MY198553A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150150108A KR101750690B1 (en) 2015-10-28 2015-10-28 Pharmaceutical composition comprising metformin and lobeglitazone
PCT/KR2016/009393 WO2017073897A1 (en) 2015-10-28 2016-08-24 Pharmaceutical composition comprising metformin and lobeglitazone

Publications (1)

Publication Number Publication Date
MY198553A true MY198553A (en) 2023-09-05

Family

ID=58630531

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018700643A MY198553A (en) 2015-10-28 2016-08-24 Pharmaceutical composition comprising metformin and lobeglitazone

Country Status (4)

Country Link
KR (1) KR101750690B1 (en)
MY (1) MY198553A (en)
PH (1) PH12018500817B1 (en)
WO (1) WO2017073897A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102369679B1 (en) * 2017-09-29 2022-03-04 한미약품 주식회사 Pharmaceutical combination comprising DAPAGLIFLOZIN L-PROLINE and METFORMIN
KR102070104B1 (en) * 2018-06-05 2020-01-29 주식회사 종근당 Controlled release pharmaceutical formulation comprising Lobeglitazone and Metformin
KR20240041755A (en) * 2022-09-23 2024-04-01 주식회사 종근당 Composition and combination therapy for treatment of type 2 diabetes mellitus
KR20240120463A (en) * 2023-01-31 2024-08-07 주식회사 종근당 Pharmaceutical composite formulation comprising lobeglitazone and sitagliptin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20010230A1 (en) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TYPE II DIABETES
EP1539144B1 (en) * 2002-09-20 2014-12-24 Andrx Labs Llc Multistage formulation containing a biguanide and a thiazolidinedione derivative
KR100812538B1 (en) 2006-10-23 2008-03-11 한올제약주식회사 Drug-controlled metformin-glymepiride combination

Also Published As

Publication number Publication date
PH12018500817B1 (en) 2023-08-18
KR101750690B1 (en) 2017-06-27
KR20170049129A (en) 2017-05-10
WO2017073897A1 (en) 2017-05-04
PH12018500817A1 (en) 2018-10-29

Similar Documents

Publication Publication Date Title
MX2015016983A (en) Nuclear transport modulators and uses thereof.
MX370792B (en) Methods and compositions for the treatment of cancer.
BR112017012406A2 (en) fixed ratio formulation of insulin glargine / lixisenatide
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2018000546A (en) Pharmaceutical composition containing celecoxib and tramadol.
WO2014153009A3 (en) Thiosaccharide mucolytic agents
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
MX2020012989A (en) Therapeutic agent for fibrosis.
TN2019000032A1 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2016014696A (en) Combinations of formoterol and budesonide for the treatment of copd.
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
MY198553A (en) Pharmaceutical composition comprising metformin and lobeglitazone
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EP3881845A3 (en) Combination of trazodone and gabapentin for the treatment of pain
BR112017014295A2 (en) pharmaceutical composition.
MX2018015240A (en) Compositions comprising timolol and their use in the treatment of rosacea by topical administration.
MX2023005681A (en) Pharmaceutical composition for treating acute and chronic pain, containing polmacoxib and tramadol.
PH12018500946A1 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
UA109242U (en) STABLE PHARMACEUTICAL COMPOSITION CONTAINING PROTEASOM INHIBITOR
MX2016010919A (en) 4-benzylsulfonyl-2-butenenitrile.
GR1008804B (en) Medical compositions containing hyaluronic acid or salts thereof, amino acids, vitamins, non-organic salts and other components
IN2014DE00822A (en)